Junko Ito
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Junko Ito has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Akira Shimatsu
Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan
1 shared publication - Akira Teramoto
Department of Neurosurgery, Nippon Medical School, Tokyo, Japan
1 shared publication - Eri Maeda
Department of Public Health, Faculty of Medicine, Hokkaido University, Sapporo
1 shared publication - Hiroyuki Tanaka
Department of Pediatrics, Okayama Saiseikai General Hospital, 1-7-18 Ifuku-cho, Kita-ku, Okayama, 700-8511, Japan
1 shared publication - Koji Takano
GH Treatment Study Committee, The Foundation for Growth Science, 5-1-16 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
1 shared publication - Kunihiko Hanew
Growth Hormone Therapy Research Committee, Foundation for Growth Science, Tokyo 113-0033, Japan
1 shared publication
Latest Publications
- Open Access
- 21 October 2016
- Published by Springer Nature in BMC Health Services Research
- Vol. 16 (1) , 602
Effects of financial support on treatment of adolescents with growth hormone deficiency: a retrospective study in Japan
Treatment costs for children with growth hormone (GH) deficiency are subsidized by the government in Japan if the children meet clinical criteria, including height limits (boys: 156.4 cm; girls: 145.4 cm). However, several funding programs, such as a subsidy provided by local governments, can be used by those who exceed the height limits. In this study, we explored the impacts of financial support on GH treatment using this natural allocation. A retrospective analysis of 696 adolescent patients (451 boys and 245 girls) who reached the height limits was conducted. Associations between financial support and continuing treatment were assessed using multiple logistic regression analyses adjusting for age, sex, height, growth velocity, bone age, and adverse effects. Of the 696 children in the analysis, 108 (15.5 %) were still eligible for financial support. The proportion of children who continued GH treatment was higher among those who were eligible for support than among those who were not (75.9 % vs. 52.0 %, P < 0.001). The odds ratios of financial support to continuing treatment were 4.04 (95 % confidence interval [CI]: 1.86–8.78) in boys and 1.72 (95 % CI: 0.80–3.70) in girls, after adjusting for demographic characteristics and clinical factors. Financial support affected decisions on treatment continuation for children with GH deficiency. Geographic variations in eligibility for financial support pose an ethical problem that needs policy attention. An appropriate balance between public spending on continuation of therapy and improved quality of life derived from it should be explored.
- 21 October 2016
- Published by Springer Nature in BMC Health Services Research
- Vol. 16 (1) , 602
Open AccessEffects of financial support on treatment of adolescents with growth hormone deficiency: a retrospective study in Japan
Treatment costs for children with growth hormone (GH) deficiency are subsidized by the government in Japan if the children meet clinical criteria, including height limits (boys: 156.4 cm; girls: 145.4 cm). However, several funding programs, such as a subsidy provided by local governments, can be used by those who exceed the height limits. In this study, we explored the impacts of financial support on GH treatment using this natural allocation. A retrospective analysis of 696 adolescent patients (451 boys and 245 girls) who reached the height limits was conducted. Associations between financial support and continuing treatment were assessed using multiple logistic regression analyses adjusting for age, sex, height, growth velocity, bone age, and adverse effects. Of the 696 children in the analysis, 108 (15.5 %) were still eligible for financial support. The proportion of children who continued GH treatment was higher among those who were eligible for support than among those who were not (75.9 % vs. 52.0 %, P < 0.001). The odds ratios of financial support to continuing treatment were 4.04 (95 % confidence interval [CI]: 1.86–8.78) in boys and 1.72 (95 % CI: 0.80–3.70) in girls, after adjusting for demographic characteristics and clinical factors. Financial support affected decisions on treatment continuation for children with GH deficiency. Geographic variations in eligibility for financial support pose an ethical problem that needs policy attention. An appropriate balance between public spending on continuation of therapy and improved quality of life derived from it should be explored.